2018
A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Giuroiu I, Ku G, Leichman L, Du K, Oh P, Levinson B, Iqbal S, Thomas C, Wu J. A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2018, 36: tps199-tps199. DOI: 10.1200/jco.2018.36.4_suppl.tps199.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaPathologic complete responseOverall survivalClinical CRRadiation therapyMedian progression-free survivalPhase IEfficacy of nivolumabCarboplatin/paclitaxelOverall survival benefitProgression-free survivalKaplan-Meier curvesSquamous cell carcinomaMulti-center studyLast dosePrimary endpointUnacceptable toxicitySurvival benefitComplete responseMeier curvesAbscopal effectCell carcinomaExtensive tumorsEsophageal cancer
2017
Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Oh P, Du K. Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports 2017, 13: 276-283. DOI: 10.1007/s11888-017-0376-3.Peer-Reviewed Original ResearchAdvanced rectal cancerRectal cancerNeoadjuvant chemoradiationComplete responsePathologic complete responseStandard of careBowel functionNeoadjuvant therapyOverall survivalTumor responsePotential complicationsChemoradiationBiologic factorsTreatment correlatesCancerSurgeryRecent reportsCurrent literatureBiomarkersResponseComplicationsPatientsTherapyCare